[go: up one dir, main page]

HRP20220208T1 - Prolijekovi riluzola i njihova primjena - Google Patents

Prolijekovi riluzola i njihova primjena Download PDF

Info

Publication number
HRP20220208T1
HRP20220208T1 HRP20220208TT HRP20220208T HRP20220208T1 HR P20220208 T1 HRP20220208 T1 HR P20220208T1 HR P20220208T T HRP20220208T T HR P20220208TT HR P20220208 T HRP20220208 T HR P20220208T HR P20220208 T1 HRP20220208 T1 HR P20220208T1
Authority
HR
Croatia
Prior art keywords
amino
methyl
thiazol
trifluoromethoxy
benzo
Prior art date
Application number
HRP20220208TT
Other languages
English (en)
Inventor
Jay Edward Wrobel
Allen B. Reitz
Jeffery Claude Pelletier
Garry Robert Smith
Haiyan Bian
Original Assignee
Biohaven Therapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd. filed Critical Biohaven Therapeutics Ltd.
Publication of HRP20220208T1 publication Critical patent/HRP20220208T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)

Claims (4)

1. Spoj koji ima formulu : [image] uključujući enantiomere, dijastereoizomere, hidrate, solvate i farmaceutski prihvatljive soli istih, pri čemu: R23 je odabrano iz grupe koja se sastoji H, CH3, CH2CH3, CH2CH2CH3, CH2CCH, CH(CH3)2, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2OH, CH2OCH2Ph, CH2CH2OCH2Ph, CH(OH)CH3, CH2Ph, CH2(cikloheksil), CH2(4-OH-Ph), (CH2)4NH2, (CH2)3NHC(NH2)NH, CH2(3-indol), CH2(5-imidazol), CH2CO2H, CH2CH2CO2H, CH2CONH2, i CH2CH2CONH2;
2. Spoj prema patentnom zahtjevu 1 odabran iz grupe koja se sastoji od: (S)-2-amino-N-(2-(metil(2-okso-2-((6-(trifluorometoksi)benzo[d]tiazol-2-il)amino)etil)amino)-2-oksoetil)propanamida; (R)-2-amino-N-(2-(metil(2-okso-2-((6-(trifluorometoksi)benzo[d]tiazol-2-il)amino)etil)amino)-2-oksoetil)propanamida; (S)-2-amino-3-metil-N-(2-(metil(2-okso-2-((6-(trifluorometoksi)benzo[d]tiazol-2-il)amino)etil)amino)-2-oksoetil)butanamida; (R)-2-amino-3-metil-N-(2-(metil(2-okso-2-((6-(trifluorometoksi)benzo[d]tiazol-2-il)amino)etil)amino)-2-oksoetil)butanamida; (S)-2-amino-N-(2-(metil(2-okso-2-((6-(trifluorometoksi)benzo[d]tiazol-2-il)amino)etil)amino)-2-oksoetil)-3-fenilpropanamida; (R)-2-amino-N-(2-(metil(2-okso-2-((6-(trifluorometoksi)benzo[d]tiazol-2-il)amino)etil)amino)-2-oksoetil)-3-fenilpropanamida; (S)-2-amino-4-metil-N-(2-(metil(2-okso-2-((6-(trifluorometoksi)benzo[d]tiazol-2-il)amino)etil)amino)-2-oksoetil)pentanamida; (R)-2-amino-4-metil-N-(2-(metil(2-okso-2-((6-(trifluorometoksi)benzo[d]tiazol-2-il)amino)etil)amino)-2-oksoetil)pentanamida; (S)-2-amino-3-hidroksi-N-(2-(metil(2-okso-2-((6-(trifluorometoksi)benzo[d]tiazol-2-il)amino)etil)amino)-2-oksoetil)propanamida; (R)-2-amino-3-hidroksi-N-(2-(metil(2-okso-2-((6-(trifluorometoksi)benzo[d]tiazol-2-il)amino)etil)amino)-2-oksoetil)propanamida; 2-(2-aminoacetamido)-N-metil-N-(2-okso-2-((6-(trifluorometoksi)benzo[d]tiazol-2-il)amino)etil)acetamida; ili farmaceutski prihvatljiva sol istog.
3. Spoj prema patentnom zahtjevu 1 pri čemu R23 je H.
4. Spoj prema patentnom zahtjevu 2 koje je 2-(2-aminoacetamido)-N-metil-N-(2-okso-2-((6-(trifluorometoksi)benzo[d]tiazol-2-il)amino)etil)acetamid.
HRP20220208TT 2015-03-03 2016-02-26 Prolijekovi riluzola i njihova primjena HRP20220208T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562127684P 2015-03-03 2015-03-03
EP16759303.7A EP3265448B1 (en) 2015-03-03 2016-02-26 Riluzole prodrugs and their use
PCT/US2016/019787 WO2016140879A1 (en) 2015-03-03 2016-02-26 Riluzole prodrugs and their use

Publications (1)

Publication Number Publication Date
HRP20220208T1 true HRP20220208T1 (hr) 2022-04-29

Family

ID=56848452

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220208TT HRP20220208T1 (hr) 2015-03-03 2016-02-26 Prolijekovi riluzola i njihova primjena

Country Status (24)

Country Link
US (9) US10639298B2 (hr)
EP (2) EP4011870A1 (hr)
JP (2) JP6700293B2 (hr)
KR (2) KR20230147746A (hr)
CN (1) CN107567438B (hr)
AU (3) AU2016226463B2 (hr)
BR (1) BR112017018832B1 (hr)
CA (1) CA2978158C (hr)
CY (1) CY1125112T1 (hr)
DK (1) DK3265448T3 (hr)
EA (1) EA034759B1 (hr)
ES (1) ES2905318T3 (hr)
HR (1) HRP20220208T1 (hr)
HU (1) HUE058204T2 (hr)
IL (2) IL253989B (hr)
LT (1) LT3265448T (hr)
MX (1) MX380828B (hr)
PH (2) PH12021550250A1 (hr)
PL (1) PL3265448T3 (hr)
PT (1) PT3265448T (hr)
RS (1) RS62915B1 (hr)
SG (2) SG10201908354VA (hr)
SI (1) SI3265448T1 (hr)
WO (2) WO2016140878A2 (hr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
RS59490B1 (sr) * 2014-11-21 2019-12-31 Biohaven Therapeutics Ltd Sublingvalna formulacija riluzola
US12295942B2 (en) * 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
SG10201908354VA (en) 2015-03-03 2019-10-30 Biohaven Pharm Holding Co Ltd Riluzole prodrugs and their use
US11911369B2 (en) 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
JP2017061430A (ja) * 2015-09-25 2017-03-30 芳男 ▲浜▼田 新規なプロドラッグ
RS65474B1 (sr) * 2016-05-20 2024-05-31 Biohaven Therapeutics Ltd Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
AU2017363804B2 (en) * 2016-11-25 2021-12-23 Genuv Inc. Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
US12201618B2 (en) * 2017-01-18 2025-01-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat Alzheimer's disease
US20180207138A1 (en) 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Methods for the treatment of tremors by positive modulation of sk channels
CN110461855B (zh) * 2017-02-28 2021-02-19 正大天晴药业集团股份有限公司 氮杂环丁烷衍生物
CN107021959A (zh) * 2017-05-02 2017-08-08 青岛科技大学 一类新型吲哚衍生物及其体外抗肿瘤活性
US20210023061A1 (en) * 2017-11-12 2021-01-28 Biohaven Pharmaceutical Holding Company Ltd. Use of riluzole prodrugs to treat ataxias
KR20210034621A (ko) * 2018-07-22 2021-03-30 바이오하벤 테라퓨틱스 리미티드 알츠하이머병 치료를 위한 릴루졸 전구약물의 용도
AU2019322889A1 (en) * 2018-08-16 2021-03-04 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases
GB201818651D0 (en) * 2018-11-15 2019-01-02 Univ Sheffield Compounds
CN114945573A (zh) * 2019-10-10 2022-08-26 拜奥海芬治疗学有限公司 髓过氧化物酶抑制剂的前药
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
CA3187323A1 (en) * 2020-06-24 2021-12-30 Biohaven Therapeutics Ltd. Compositions and methods for treating obsessive-compulsive disorder
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US20240082340A1 (en) * 2021-01-18 2024-03-14 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
EP4294384A4 (en) * 2021-02-22 2025-06-25 Yale University TARGETED BIFUNCTIONAL DEGRADING AGENTS
KR102785404B1 (ko) 2022-08-19 2025-03-21 부산대학교 산학협력단 리루졸 유도체 및 이를 유효성분으로 포함하는 대장 표적성 염증성 장질환 예방 또는 치료용 조성물
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用
JP2025519970A (ja) * 2022-06-26 2025-06-26 バイオヘイブン・セラピューティクス・リミテッド リルゾールのプロドラッグを用いた神経膠芽腫を治療する方法
CN118085016B (zh) * 2024-04-24 2024-07-30 天津卡普希科技有限公司 一种d-苯甘氨酰-甘氨酸的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043319B1 (en) * 1997-11-05 2005-03-16 Mitsubishi Chemical Corporation Novel alkylamino derivatives
WO2002100399A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
WO2005037845A1 (en) * 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
CN1984880B (zh) * 2004-07-21 2010-09-22 三井化学株式会社 二胺衍生物、其制备方法及将其作为有效成分的杀菌剂
PL2982372T3 (pl) 2005-04-05 2020-12-28 Yale University Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
WO2013192610A2 (en) 2012-06-23 2013-12-27 Fox Chase Chemical Diversity Center, Inc. Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
SG10201908354VA (en) 2015-03-03 2019-10-30 Biohaven Pharm Holding Co Ltd Riluzole prodrugs and their use
US12295942B2 (en) * 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
EP3377111B1 (en) 2015-11-19 2023-11-29 Biohaven Pharmaceutical Holding Company Ltd. Amine prodrugs of pharmaceutical compounds
RS65474B1 (sr) * 2016-05-20 2024-05-31 Biohaven Therapeutics Ltd Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
US20210023061A1 (en) 2017-11-12 2021-01-28 Biohaven Pharmaceutical Holding Company Ltd. Use of riluzole prodrugs to treat ataxias

Also Published As

Publication number Publication date
MX380828B (es) 2025-03-12
BR112017018832B1 (pt) 2023-12-26
WO2016140879A9 (en) 2016-11-03
EA034759B1 (ru) 2020-03-17
JP6700293B2 (ja) 2020-05-27
HUE058204T2 (hu) 2022-07-28
JP2020128401A (ja) 2020-08-27
IL278080B (en) 2022-03-01
BR112017018832A2 (pt) 2018-04-24
AU2022202163A1 (en) 2022-04-21
AU2016226463A1 (en) 2017-09-21
EP4011870A1 (en) 2022-06-15
JP2018508525A (ja) 2018-03-29
CN107567438B (zh) 2021-06-29
WO2016140878A9 (en) 2016-10-20
SG10201908354VA (en) 2019-10-30
US12213965B2 (en) 2025-02-04
HK1248706A1 (en) 2018-10-19
SG11201706831RA (en) 2017-09-28
US12005047B2 (en) 2024-06-11
ES2905318T3 (es) 2022-04-07
US12005046B2 (en) 2024-06-11
US20230017637A1 (en) 2023-01-19
US11052070B2 (en) 2021-07-06
US20200289475A1 (en) 2020-09-17
WO2016140879A1 (en) 2016-09-09
US20210236471A1 (en) 2021-08-05
US20240091205A1 (en) 2024-03-21
US10639298B2 (en) 2020-05-05
IL253989B (en) 2020-11-30
PH12021550250A1 (en) 2022-09-05
SI3265448T1 (sl) 2022-04-29
MX2017011196A (es) 2018-05-22
US20230381149A1 (en) 2023-11-30
US10485791B2 (en) 2019-11-26
KR102587894B1 (ko) 2023-10-12
IL253989A0 (en) 2017-10-31
PT3265448T (pt) 2022-02-04
IL278080A (en) 2020-11-30
KR20180008402A (ko) 2018-01-24
PL3265448T3 (pl) 2022-04-25
WO2016140878A2 (en) 2016-09-09
AU2020233650B2 (en) 2022-04-07
US20200085794A1 (en) 2020-03-19
US20180036290A1 (en) 2018-02-08
KR20230147746A (ko) 2023-10-23
LT3265448T (lt) 2022-04-11
PH12017501576A1 (en) 2018-03-12
AU2022202163B2 (en) 2024-02-29
JP7012117B2 (ja) 2022-02-10
US20230381150A1 (en) 2023-11-30
AU2020233650A1 (en) 2020-10-08
CN107567438A (zh) 2018-01-09
CY1125112T1 (el) 2024-02-16
AU2016226463B2 (en) 2020-06-25
EA201791951A1 (ru) 2018-01-31
EP3265448B1 (en) 2021-12-29
EP3265448A4 (en) 2018-11-07
RS62915B1 (sr) 2022-03-31
EP3265448A1 (en) 2018-01-10
DK3265448T3 (da) 2022-03-28
PH12017501576B1 (en) 2021-11-05
US20180037557A1 (en) 2018-02-08
CA2978158C (en) 2022-04-12
WO2016140878A3 (en) 2016-11-24
CA2978158A1 (en) 2016-09-09
US10905681B2 (en) 2021-02-02

Similar Documents

Publication Publication Date Title
HRP20220208T1 (hr) Prolijekovi riluzola i njihova primjena
HRP20240617T1 (hr) Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
HRP20220920T1 (hr) Pirolo[1,2-f][1,2,4]triazini koji su korisni za liječenje infekcija respiratornim sincicijalnim virusom
AR114827A1 (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
MA54458A (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
EP3759109C0 (en) Substituted pyrrolizine compounds as hbv replication inhibitors
PL3638665T3 (pl) Chwastobójczo skuteczne 3-fenyloizoksazolino-5-karboksyamidy kwasów i estrów tetrahydro- i dihydrofuranokarboksylowych
MA54452A (fr) Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
EP3870178A4 (en) Crystalline forms of mnk inhibitors
MA46866A (fr) Une forme cristalline d'un inhibiteur de magl
PE20151722A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
HRP20130976T1 (hr) Karbonilaminopirolopirazoli, potentni inhibitori kinaza
MA50655A (fr) Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
MA55614A (fr) Formes cristallines d'inhibiteur de pyridazinone trpc
RS50823B (sr) Supstituisani 1h-pirolo[3,2-b, 3,2-c, i 2,3-c]piridin-2-karboksamidi i srodni analozi kao inhibitori kazein kinaze i epsilon
FI3572405T3 (fi) Benzoimidatsol-1,2-yyli amidit kv7 kanavan aktivaattoreina
EP4210833A4 (en) CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP3946364A4 (en) Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof
HRP20240643T1 (hr) Heterociklički spojevi za inhibiciju aktivnosti tyk2
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы
RS64679B1 (sr) Diazabiciklooktanoni kao inhibitori serinskih beta-laktamaza
MA54526A (fr) NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta
EP3905958C0 (en) PATIENT HEAD PROTECTION DEVICE
HRP20241163T1 (hr) Antiproliferacijski spojevi i njihova uporaba